---
document_datetime: 2025-12-19 09:24:56
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ruconest-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ruconest-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3687873
conversion_datetime: 2026-01-03 12:53:58.009848
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ruconest

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 27/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000263304                     | PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from Ruconest EU registry listed as a category 3 study in the RMP. This is a non-imposed non- interventional PASS (phase IV) of C1 inhibitor Treatment Registry to assess the Safety and Immunological Profile of Ruconest in the treatment of HAE Attacks. Version 21.0 of the RMP has also been submitted.   |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000267751 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/05/2025 | N/A |             |
| PSUR / EMA/PSUR/0000248470            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Maintenance |
| PSUR / EMA/PSUR/0000288246            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Maintenance |